Gynae BT 2017

Next generation of clinical trials based on IGABT + IGRT as CCRT - Hypothesis driven -  Comparative Trials on IGABT vs. 2D (randomized)  Dose escalation for advanced disease HR CTV (LC, OS)

 Dose de-escalation for limited and favourable

advanced disease (good response,…) (Morb/QoL)

 Systematic Introduction of IMRT/IGRT (Morb/QoL

 Para-aortic RT, SIB (Lymphnode) (NC, OS)

 Systematic concomitant radiochemotherapy min. 5 cycl for subgroups with high risk of distant metastases (OS)  Testing Dose/Volume constraints for Target and OARs  Biomarker investigation (Hypoxia, HPV, EGFR) VEGF..)